Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
Total Valuation
Context Therapeutics has a market cap or net worth of $84.57M. The enterprise value is -$21.04K.
Market Cap$84.57M
Enterprise Value-$21.04K
Share Statistics
Context Therapeutics has 89,704,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding89,704,190
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Context Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -31.34%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-31.34%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-2.23M
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Context Therapeutics is -2.30. Context Therapeutics’s PEG ratio is 0.03.
PE Ratio-2.30
PS Ratio―
PB Ratio0.64
Price to Fair Value0.64
Price to FCF-2.09
Price to Operating Cash Flow-4.21
PEG Ratio0.03
Income Statement
In the last 12 months, Context Therapeutics had revenue of 0.00 and earned -26.73M in profits. Earnings per share was -0.46.
Revenue0.00
Gross Profit0.00
Operating Income-29.92M
Pretax Income-26.73M
Net Income-26.73M
EBITDA-29.92M
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was -4.91M and capital expenditures -7.32K, giving a free cash flow of -4.91M billion.
Operating Cash Flow-4.91M
Free Cash Flow-4.91M
Free Cash Flow per Share-0.05
Dividends & Yields
Context Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change-27.69%
50-Day Moving Average0.78
200-Day Moving Average1.55
Relative Strength Index (RSI)63.22
Average Volume (3m)193.11K
Important Dates
Context Therapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Context Therapeutics as a current ratio of 35.62, with Debt / Equity ratio of 0.23%
Current Ratio35.62
Quick Ratio35.62
Debt to Market Cap<0.01
Net Debt to EBITDA3.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Context Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Context Therapeutics EV to EBITDA ratio is 1.10, with an EV/FCF ratio of 1.12.
EV to Sales0.00
EV to EBITDA1.10
EV to Free Cash Flow1.12
EV to Operating Cash Flow2.26
Balance Sheet
Context Therapeutics has $94.43M in cash and marketable securities with $55.08K in debt, giving a net cash position of -$94.21M billion.
Cash & Marketable Securities$94.43M
Total Debt$55.08K
Net Cash-$94.21M
Net Cash Per Share-$1.05
Tangible Book Value Per Share$1.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Context Therapeutics is $4.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.50
Price Target Upside378.72% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast65.02%